2023-05-11T10:16:26-05:00 2022-12-31 410746749 CLIFTONLARSONALLEN LLP 2210 EAST ROUTE 66 GLENDORA CA 91740 990 2022-01-01 593187624 JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC JAEB 8139758690 15310 AMBERLY DRIVE 350 TAMPA FL 33647 ROY W BECK MD PHD EXECUTIVE DIRECTOR 8139758690 2023-05-09 1 ROY BECK MD PHD 999009999 0 TINA HENTON P00630282 6268577300 2023-05-04 0 AAL1 IAL1 2022 2023-04-26 12:10:37Z ROY W BECK MD PHD 15310 AMBERLY DRIVE 350 TAMPA FL 33647 37806927 0 X WWW.JAEB.ORG X 1998 FL DESIGN AND CONDUCT CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH 5 4 167 6 0 0 30943273 37801756 0 0 2389 5171 0 0 30945662 37806927 2005000 3161 0 0 15409998 17020908 0 0 0 16325423 17312640 33740421 34336709 -2794759 3470218 6686378 10449118 11691133 14538729 -5004755 -4089611 X DESIGN AND CONDUCT CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH 0 0 27382649 3161 SEE SCHEDULE O DURING 2022, JCHR HAD 49 ACTIVE CLINICAL STUDIES. IN ADDITION TO INDUSTRY COLLABORATIONS, JCHR RECEIVED GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (8), HELMSLEY CHARITABLE TRUST (10), JDRF (5), FOUNDATION FIGHTING BLINDNESS (5), CYSTIC FIBROSIS FOUNDATION (2), AND FOOD AND DRUG ADMINISTRATION (1). JCHR ALSO SELF-FUNDED ONE STUDY AND NUMEROUS STATISTICAL ANALYSIS PROJECTS USING DATASETS FROM PREVIOUSLY COMPLETED STUDIES. SEVERAL STUDIES ARE FUNDED BY MULTIPLE SOURCES. FOR EXAMPLE, ONE CLINICAL TRIAL EVALUATING FENOFIBRATE FOR DIABETIC RETINOPATHY IS A LARGE COLLABORATION WITH FUNDS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH (NATIONAL EYE INSTITUTE AND NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASE), JDRF, HELMSLEY CHARITABLE TRUST, AND ROCHE. NINE NEW GRANTS, CONTRACTS, OR SUBAWARDS BEGAN DURING THE YEAR. AMONG 2,859 ENTITIES RECEIVING NIH FUNDING IN 2022, JCHR RANKS IN THE TOP 9%. OUT OF 65,306 NIH GRANTS PROVIDED IN 2022, JCHR HAD THE 173RD (TOP 0.3%) AND 581ST (TOP 0.9%) LARGEST GRANTS (SOURCE: BLUE RIDGE INSTITUTE FOR MEDICAL RESEARCH, 2022). JCHR PROJECTS HAD 62 MANUSCRIPTS ACCEPTED OR PUBLISHED AND 53 PRESENTATIONS MADE AT NATIONAL AND INTERNATIONAL MEETINGS IN 2022. RESULTS FROM THESE MANUSCRIPTS INCLUDE THE FOLLOWING FOUR THAT WERE PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE: A RANDOMIZED TRIAL OF BIONIC PANCREAS TREATMENT IN TYPE 1 DIABETES DEMONSTRATED THAT AT 13 WEEKS, BIONIC PANCREAS USE WAS ASSOCIATED WITH A GREATER REDUCTION IN HBA1C THAN STANDARD CARE. UNLIKE CURRENTLY AVAILABLE SEMIAUTOMATED INSULIN-DELIVERY SYSTEMS, THE BIONIC PANCREAS DOES NOT REQUIRE CARBOHYDRATE COUNTING FOR ROUTINE OPERATION. A RANDOMIZED TRIAL IN VERY YOUNG CHILDREN WITH TYPE 1 DIABETES (AGES 1 TO 7) SHOWED IMPROVED GLYCEMIC CONTROL WITH THE USE OF A HYBRID CLOSED-LOOP SYSTEM (I.E., ARTIFICIAL PANCREAS) WITHOUT INCREASING TIME SPENT IN HYPOGLYCEMIC RANGE. A RANDOMIZED TRIAL IN YOUTHS (10 TO <17 YEARS) WITH NEW ONSET TYPE 1 DIABETES DEMONSTRATED THAT HYBRID CLOSED-LOOP THERAPY DID NOT PREVENT THE DECLINE OF RESIDUAL C-PEPTIDE SECRETION OVER 24 MONTHS COMPARED WITH STANDARD INSULIN TREATMENT. A RANDOMIZED TRIAL IN EYES WITH DIABETIC MACULAR EDEMA WITH MODERATE VISION LOSS FOUND NO SIGNIFICANT DIFFERENCE IN VISUAL ACUITY OVER TWO YEARS BETWEEN INJECTIONS OF AFLIBERCEPT MONOTHERAPY (~$1,830 PER INJECTION) AND INJECTIONS OF BEVACIZUMAB FIRST (~$70 PER INJECTION) WITH A SWITCH TO AFLIBERCEPT WHEN THERE WAS SUBOPTIMAL RESPONSE.IN ADDITION TO CONVENTIONAL CLINIC-BASED CLINICAL TRIALS, JCHR CONDUCTED SEVERAL "DIRECT TO-PATIENT" STUDIES IN WHICH JCHR STAFF HAD VIRTUAL CONTACT WITH STUDY PARTICIPANTS WHO PROVIDED DATA VIA THE INTERNET AND FROM DEVICES: (1) A STUDY TO COLLECT DEVICE DATA DURING EXERCISE IN ADULTS WITH TYPE 1 DIABETES; (2) A STUDY TO COLLECT DEVICE DATA DURING EXERCISE IN YOUTH WITH TYPE 1 DIABETES; (3) A STUDY TO PROVIDE VIRTUAL CLINIC SUPPORT FOR ADULTS WITH TYPE 1 OR TYPE 2 DIABETES THAT INCLUDED SUPPORT FOR THE USE OF DIABETES TECHNOLOGY AS WELL AS BEHAVIORAL HEALTH SUPPORT; AND (4) A STUDY TO COLLECT REAL-WORLD DATA FROM A DIABETES MANAGEMENT SYSTEM THAT DISPLAYS AND TRACKS HEALTHCARE PROVIDER-RECOMMENDED INSULIN DOSING INFORMATION. 27382649 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 88 0 1 167 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 X ROY W BECK MD PHD 8139758690 15310 AMBERLY DRIVE 350 TAMPA FL 33647 ROY W BECK MD PHD PRESIDENT 40.00 1.00 X X 461990 0 84664 RAMESH AYYALA DIRECTOR (THRU 10/2022) 1.00 1.00 X 0 0 0 ANNE LINDBLAD DIRECTOR 1.00 1.00 X 0 0 0 SHAN SHIKARPURI DIRECTOR 1.00 1.00 X 0 0 0 LESLEY ZAJAC DIRECTOR (THRU 10/2022) 1.00 1.00 X 0 0 0 DANA BALL DIRECTOR 1.00 1.00 X 0 0 0 NEIL BRESSLER DIRECTOR 1.00 1.00 X 0 0 0 ADAM GLASSMAN EXECUTIVE DIRECTOR 40.00 0.00 X 300510 0 51376 ERICA VOGT CHIEF FINANCIAL OFFICER 40.00 0.00 X 154386 0 19711 JEANNIE PERKINS CHF RESEARCH COMP. OFFICER 40.00 0.00 X 180493 0 21124 ROBIN GAL EPIDEMIOLOGIST IV 40.00 0.00 X 177631 0 10884 CRAIG KOLLMAN DIRECTOR OF BIOSTATISTICS 40.00 0.00 X 231304 0 37382 B MICHELE MELIA BIOSTATISTICIAN V 40.00 0.00 X 208285 0 24199 PETER CALHOUN BIOSTATISTICIAN IV 40.00 0.00 X 173794 0 27272 RAYMOND KRAKER EPIDEMIOLOGIST IV 40.00 0.00 X 159505 0 37692 ALLISON AYALA BIOSTATISTICIAN IV 40.00 0.00 X 158228 0 35935 2206126 0 350239 42 0 1 0 JOSLIN DIABETES CENTER INC 1 JOSLIN PLACE BOSTON MA 02115 CONSULTING / STUDY PARTICIPANT MEDICAL S 571963 MAYO CLINIC PO BOX 860334 MINNEAPOLIS MN 55486 CONSULTING / STUDY PARTICIPANT MEDICAL S 564032 UNIVERSITY OF PENNSYLVANIA 3400 CIVIC CENTER BLVD PHILADELPHIA PA 19104 CONSULTING / STUDY PARTICIPANT MEDICAL S 539125 CECELIA HEALTH INC 1601 THIRD AVENUE SUITE 11-J NEW YORK NY 10128 CONSULTING / STUDY PARTICIPANT MEDICAL S 436757 HEALTHPARTNERS INSTITUTE 8170 33RD AVENUE SOUTH MINNEAPOLIS MN 55425 CONSULTING / STUDY PARTICIPANT MEDICAL S 431075 44 2797726 15016968 19987062 37801756 5171 5171 37806927 0 0 5171 3161 3161 1462769 538380 924389 11345826 8766061 2579765 1644364 1221969 422395 1553287 1131293 421994 1014662 739001 275661 69515 69515 88278 88278 322441 280768 41673 25181 20735 4446 404951 283856 121095 755504 189209 566295 117628 8560 109068 540488 521384 19104 1404 1404 1139380 1139380 168033 30760 137273 SUBCONTRACTOR PAYMENTS 11975772 11975772 RESEARCH EXPENSES 1538558 1535627 2931 HUMAN RESOURCE EXPENSES 42979 35391 7588 TRAINING 16493 13410 3083 106035 87312 18723 34336709 27382649 6954060 0 2737260 4590445 2281341 5073199 131 0 183416 2104334 1954413 332705 149921 1334941 452137 6686378 10449118 1263471 1406415 8585291 12707254 1842371 425060 11691133 14538729 X -5004755 -4089611 -5004755 -4089611 6686378 10449118 3470218 -2555074 0 X 0 1 X 1 1 1 X 34277822 31955018 36874622 30943273 37801756 171852491 34277822 31955018 36874622 30943273 37801756 171852491 24056926 147795565 387 219897 59752 2389 5171 287596 172140087 0.85860 0.83100 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 520608 507629 12979 1297051 1164158 132893 286675 282626 4049 149921 RIGHT OF USE ASSETS 415813 SECURITY DEPOSIT 36324 452137 LEASE LIABILITY 425060 425060 X X 0 0 0 0 0 0 0 0 0 ROY W BECK MD PHD PRESIDENT 390826 0 0 0 71164 0 40500 0 44164 0 546654 0 0 0 ADAM GLASSMAN EXECUTIVE DIRECTOR 242634 0 0 0 57876 0 14000 0 37376 0 351886 0 0 0 CRAIG KOLLMAN DIRECTOR OF BIOSTATISTICS 187112 0 0 0 44192 0 10690 0 26692 0 268686 0 0 0 B MICHELE MELIA BIOSTATISTICIAN V 170046 0 0 0 38239 0 9250 0 14949 0 232484 0 0 0 JEANNIE PERKINS CHF RESEARCH COMP. OFFICER 146869 0 0 0 33624 0 8000 0 13124 0 201617 0 0 0 PETER CALHOUN BIOSTATISTICIAN IV 140722 0 0 0 33072 0 8000 0 19272 0 201066 0 0 0 RAYMOND KRAKER EPIDEMIOLOGIST IV 127069 0 0 0 32436 0 7846 0 29846 0 197197 0 0 0 ALLISON AYALA BIOSTATISTICIAN IV 126293 0 0 0 31935 0 7725 0 28210 0 194163 0 0 0 ROBIN GAL EPIDEMIOLOGIST IV 146626 0 0 0 31005 0 7500 0 3384 0 188515 0 0 0 ERICA VOGT CHIEF FINANCIAL OFFICER 125750 0 0 0 28636 0 6927 0 12784 0 174097 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS REVIEWS AND APPROVES FORM 990 PRIOR TO THE FORM'S FILING. FORM 990, PART VI, SECTION B, LINE 12C ANY DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS, WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST AND BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE DIRECTORS, AND MEMBERS OF COMMITTEES WITH GOVERNING BOARD DELEGATED POWERS CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE HE/SHE SHALL LEAVE THE GOVERNING BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. IF THE GOVERNING BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE A MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM THE MEMBER OF THE BASIS FOR SUCH BELIEF AND AFFORD THE MEMBER AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF THE GOVERNING BOARD OR COMMITTEE DETERMINES THE MEMBER HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. EACH DIRECTOR, PRINCIPAL OFFICER AND MEMBER OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS SHALL ANNUALLY SIGN A STATEMENT WHICH AFFIRMS SUCH PERSON HAS RECEIVED A COPY OF THE CONFLICTS OF INTEREST POLICY, HAS READ AND UNDERSTANDS THE POLICY, HAS AGREED TO COMPLY WITH THE POLICY, AND UNDERSTANDS THE ORGANIZATION IS CHARITABLE AND IN ORDER TO MAINTAIN ITS FEDERAL TAX EXEMPTION THEY MUST ENGAGE PRIMARILY IN ACTIVITIES WHICH ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES. FORM 990, PART VI, SECTION B, LINE 15 EACH YEAR THE SALARY SUBCOMMITTEE OF THE BOARD OF DIRECTORS MEETS TO DETERMINE THE SALARY FOR THE PRESIDENT, EXECUTIVE DIRECTOR, AND THE CHIEF RESEARCH COMPLIANCE OFFICER. THIS WAS MOST RECENTLY COMPLETED IN DECEMBER 2022. AN INDEPENDENT CONSULTING FIRM WAS HIRED IN 2009 TO ASSESS THE COMPENSATION OF THE PRESIDENT AND ROBUST COMPARABILITY DATA WAS USED. POST-ASSESSMENT, THE PRESIDENT HAS RECEIVED ONLY COST OF LIVING SALARY INCREASES. THE SAME INDEPENDENT CONSULTING FIRM WAS HIRED IN 2021 TO ASSESS THE COMPENSATION OF THE EXECUTIVE DIRECTOR AND ROBUST COMPARABILITY DATA WAS USED. POST-ASSESSMENT, THE EXECUTIVE DIRECTOR HAS RECEIVED ONLY COST OF LIVING SALARY INCREASES. FORM 990, PART VI, SECTION C, LINE 19 ANY MEMBER OF THE PUBLIC CAN COME IN AND INSPECT THE PUBLICLY AVAILABLE PORTLONS OF OUR GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS IN OUR OFFICE DURING REGULAR OFFICE HOURS. JAEB CENTER RESEARCH TRUST INC 15310 AMBERLY DRIVE TAMPA FL 33647 270717710 SUPPORT FL 501(C)(3) LINE 12B, II N/A 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 JAEB CENTER RESEARCH TRUST INC C 2797726 CASH JAEB CENTER RESEARCH TRUST INC B 161 CASH JAEB CENTER RESEARCH TRUST INC N SEE NOTE JAEB CENTER RESEARCH TRUST INC O SEE NOTE SCHEDULE R, PART V, ITEMS N AND O: THE ORGANIZATION SHARES FACILITIES, EQUIPMENT AND PAID EMPLOYEES WITH JAEB CENTER RESEARCH TRUST, INC. NEITHER ORGANIZATION ASSIGNS A VALUE TO THIS TRANSACTION.